ACRS Q3 2025 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$435M

Q3 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$3M-24.1% YoY

Gross Profit

$3M83.7% margin

Operating Income

-$17M-519.8% margin

Net Income

-$15M-443.0% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+85.6%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$176M

Total Liabilities

$55M

Stockholders' Equity

$120M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-24.1%
Gross Profit	$3M	$2M	+42.5%
Operating Income	-$17M	-$10M	-63.8%
Net Income	-$15M	-$8M	-92.6%

Revenue Segments

License and Service

$3M85%

Contract research

$485,00015%